Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. sits in the top decile of US sponsors by registered trial count (#238 of 15,742 sponsors by registered trial count).
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.: 102 sponsored US clinical trials, none currently recruiting.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. sponsors 102 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 83 completed. 38 of these trials are in Phase 3-4 (later-stage) and 62 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 3 trials.
Top-decile sponsor footprint
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. ranks in the top decile of sponsors by registered trial count (#238 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
83 of 102 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
102 total, page 2 of 3
A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.
NCT00613938
A Study Evaluating Effects of Intranasal JNJ-17166864 on Symptoms of Allergic Rhinitis in Adults
NCT00604123
A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
NCT00576732
A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.
NCT00566449
A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression
NCT00566202
A Study to Investigate Whether Pharmacokinetic and Pharmacodynamic Interactions Exist Between Metformin and Canagliflozin (JNJ-28431754) in Healthy Volunteers
NCT01756417
Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to Paliperidone
NCT00535132
A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia
NCT01150448
An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With Schizophrenia
NCT00524043
A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients
NCT00518323
PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients
NCT00440466
Effectiveness and Safety Study for JNJ-18054478 in Asthma Patients.
NCT00530166
Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers
NCT01756404
An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain
NCT00487435
An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer
NCT00580112
A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus
NCT00963768
Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma
NCT00579501
An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis
NCT00455429
Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia
NCT00589914
Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia
NCT00590577
Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.
NCT00412373
Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
NCT00425321
An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation
NCT00403767
A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain
NCT00361504
An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis
NCT00402688
A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy
NCT00386152
A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety
NCT00364533
An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease
NCT00440557
A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy
NCT00267007
A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder
NCT00490971
A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder
NCT00309699
Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa
NCT00210626
Topiramate as Adjunctive Therapy in Infants 1-24 Months for the Control of Partial Onset Seizures
NCT00113815
An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer
NCT00113607
A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes
NCT00132678
A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.
NCT00111189
A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma
NCT00097981
Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy
NCT00095134
A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer
NCT00091442
An Observational Study for Analysis of Mortality in Participants Who Participated in Previous 3 Studies of Galantamine
NCT00297414
To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older
NCT00082095
Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy
NCT00083434
Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy
NCT00083486
A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer
NCT00072670
Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis
NCT00086684
Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00061802
A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
NCT00060944
Safety and Efficacy of Study Drug Versus Placebo for Negative Symptoms of Schizophrenia
NCT00063297
Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer
NCT00050141
A Study of Incidence of Musculoskeletal Disorders in Children Who Have Received Levofloxacin or a Standard Non-Fluoroquinolone Therapy for Acute Bacterial Infection
NCT00210639
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 33 |
| Phase 2 | 29 |
| Phase 3 | 32 |
| Phase 4 | 6 |
Therapeutic Areas
How the Johnson & Johnson Pharmaceutical Research & Development, L.L.C. early-phase archive is shaped
102 indexed studies, none listed as recruiting (0% open); 83 completed (81%).
Phase mix: 38 late (III/IV) vs 62 early (I/II) (early-phase heavy).
Top condition: Healthy (3 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.: archived-pipeline peers nationwide
Peers matched on 102 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 102 archived trials
- Butler Hospital · 103 trials · 9% recruiting
- Spaulding Rehabilitation Hospital · 101 trials · 19% recruiting
- Boston University Charles River Campus · 104 trials · 22% recruiting
- Kessler Foundation · 104 trials · 33% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Johnson & Johnson Pharmaceutical Research & Development, L.L.C. page
102 registered trials is a research-attention snapshot, not an endorsement of Johnson & Johnson Pharmaceutical Research & Development, L.L.C. or any single study.
- None of Johnson & Johnson Pharmaceutical Research & Development, L.L.C.'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Healthy is the condition Johnson & Johnson Pharmaceutical Research & Development, L.L.C. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. pipeline card: 102 registered trials from official public datasets.Report a data error.